OncoMatch/Clinical Trials/NCT06311578
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Is NCT06311578 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including JNJ-87704916 and Cetrelimab for neoplasms.
Treatment: JNJ-87704916 · Cetrelimab — The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage IV, III
metastatic or locally advanced NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available standard of care therapy
advanced or metastatic solid tumor exhausting all available standard of care therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NYU Langone Health · New York, New York
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
- UPMC Cancer Centers · Pittsburgh, Pennsylvania
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06311578 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received all available standard of care therapy.
What disease stage is eligible?
Stage IV or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify